US FDA approves BridgeBio drug for rare heart disease
The US FDA approved BridgeBio’s drug for a rare and deadly heart disease, transthyretin amyloid cardiomyopathy, making it the first new treatment in a market dominated by Pfizer. Transthyretin amyloid cardiomyopathy is a disease in which defective transthyretin proteins accumulate in the heart and can lead to organ failure.
ПОПУЛЯРНЫЕ ПОСТЫ
North Carolina city sues Duke Energy over climate crisis
Декабрь 6, 2024
Earthquake of magnitude 5.7 strikes western Iran
Декабрь 6, 2024
Soy traders push to soften ban on buying Amazon produce
Декабрь 6, 2024
Tom Tykwer’s ‘The Light’ will open the 2025 Berlin Film Festival
Декабрь 6, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ